BRUKER CORP (BRKR): Results of Operations and Financial Condition
BRUKER CORP (BRKR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 brkr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bruker Reports Second Quarter 2026 Financial Results • Q2-26 Bruker Scientific Instruments (BSI) bookings up 10% organically year-over-year (yoy), with BSI book-to-bill >1.0x • Q2-26 revenue of $838.5 million, up +5.2% yoy; u
How this was made
The 30-second read
Why it matters
Traders can update models using the new Q2 datapoints and the revised FY2026 revenue and non-GAAP EPS ranges, while noting management’s guidance change is limited to currency and tax.
Market read
The filing provides fresh quarterly performance and a specific FY2026 non-GAAP EPS range ($2.10 to $2.15), supporting near-term positioning in BRKR.
What to watch
GAAP results include $134.9M non-cash goodwill impairment charges, which can keep longer-term risk perception elevated even if non-GAAP profitability improves.
Background
This is Bruker’s SEC Form 8-K (Item 2.02) with Q2 2026 results and an FY2026 outlook update.
Ticker impact
Bruker reported Q2 2026 revenue of $838.5M, non-GAAP EPS of $0.49, and updated FY2026 guidance for currency and tax only.
Likely modest positive bias for BRKR as traders price in improved non-GAAP EPS range ($2.10 to $2.15) and margin expansion, with upside capped by the guidance being currency/tax-only.
The filing provides concrete quarterly results (revenue growth, non-GAAP EPS) and a specific FY2026 non-GAAP EPS range increase versus FY25, while stating the revenue and EPS outlook is updated only for currency and tax, reducing the probability of a major fundamental re-rating from this release alone.
Market effects
Scientific instruments and semiconductor tools demand signals (BSI bookings up 10% organically, BSI book-to-bill >1.0) may support sentiment across lab/analytical instrumentation peers.
No explicit regional macro shock; commentary highlights stronger aca/gov bookings in Europe and China versus soft US academic demand.
Currency and tax sensitivity is emphasized, which can matter for multinational instrumentation names with similar FX exposure.
Counterpoint
Because the company says FY2026 guidance is updated for currency and tax only, the market may overreact to the EPS range without a corresponding organic growth acceleration.
Key entities
- companyBruker Corporation
Reported Q2 2026 financial results and updated FY2026 guidance for currency and tax only.
- segmentBruker Scientific Instruments (BSI)
Bookings up 10% organically YoY; BSI book-to-bill >1.0x; Q2 revenue $767.3M.
- segmentBruker Energy & Supercon Technologies (BEST)
Q2 revenue $74.2M, up 11.9% YoY with 8.9% organic growth net of intercompany eliminations.
